185563-92-2

Usage

Molecular structure

The compound consists of an isoindole-1,3-dione core attached to a 2-[1-(triphenylmethyl)-1H-imidazol-2-yl] substituent.

Heterocyclic compound

The isoindole-1,3-dione core contains two oxygen atoms in its five-membered ring structure, while the imidazole substituent is a five-membered heterocyclic ring with three nitrogen and two carbon atoms.

Complexity

The compound is a complex organic molecule due to the presence of multiple heterocyclic rings and various substituents.

Potential applications

1H-Isoindole-1,3(2H)-dione, 2-[1-(triphenylmethyl)-1H-imidazol-2-yl]may have applications in organic synthesis, pharmaceuticals, or materials science.

Reactivity

The specific properties and reactivity of the compound determine its potential uses and effects.

Further research

Additional research and analysis are needed to fully understand the potential uses and effects of this chemical.

Upstream product

• 76-83-5 trityl chloride 
• 85-44-9 phthalic anhydride 
• 185563-91-1 phthalimidyl imidazole 

Downstream Products

• 258845-39-5 2-(3,5-dichloro-biphenyl-4-sulfonylamino)-3-({5-[4-(1-trityl-1H-imidazol-2-ylamino)-butyl]-4,5-dihydro-isoxazole-3-carbonyl}-amino)-propionic acid 
• 258845-40-8 2-(3,5-dimethyl-biphenyl-4-sulfonylamino)-3-({5-[4-(1-trityl-1H-imidazol-2-ylamino)-butyl]-4,5-dihydro-isoxazole-3-carbonyl}-amino)-propionic acid 
• 185563-99-9 2-(2,4,6-trimethyl-benzenesulfonylamino)-3-({5-[4-(1-trityl-1H-imidazol-2-ylamino)-butyl]-4,5-dihydro-isoxazole-3-carbonyl}-amino)-propionic acid tert-butyl ester 
• 258845-37-3 2-(2,6-dichloro-benzenesulfonylamino)-3-({5-[4-(1-trityl-1H-imidazol-2-ylamino)-butyl]-4,5-dihydro-isoxazole-3-carbonyl}-amino)-propionic acid 
• 185564-00-5 2-(2,4,6-trimethyl-benzenesulfonylamino)-3-({5-[4-(1-trityl-1H-imidazol-2-ylamino)-butyl]-4,5-dihydro-isoxazole-3-carbonyl}-amino)-propionic acid 
• 258845-44-2 2-(biphenyl-4-sulfonylamino)-3-({5-[4-(1-trityl-1H-imidazol-2-ylamino)-butyl]-4,5-dihydro-isoxazole-3-carbonyl}-amino)-propionic acid 
• 258845-42-0 2-(naphthalene-1-sulfonylamino)-3-({5-[4-(1-trityl-1H-imidazol-2-ylamino)-butyl]-4,5-dihydro-isoxazole-3-carbonyl}-amino)-propionic acid 
• 258845-46-4 2-(2,4,6-trimethyl-benzenesulfonylamino)-3-({5-[2-(1-trityl-1H-imidazol-2-ylamino)-ethyl]-4,5-dihydro-isoxazole-3-carbonyl}-amino)-propionic acid 
• 258845-43-1 2-(3,5-dimethyl-isoxazole-4-sulfonylamino)-3-({5-[4-(1-trityl-1H-imidazol-2-ylamino)-butyl]-4,5-dihydro-isoxazole-3-carbonyl}-amino)-propionic acid 
• 258845-41-9 2-benzenesulfonylamino-3-({5-[4-(1-trityl-1H-imidazol-2-ylamino)-butyl]-4,5-dihydro-isoxazole-3-carbonyl}-amino)-propionic acid 

Relevant academic research and scientific papers

Isoxazolines as potent antagonists of the integrin α(v)β3

Starting with lead compound 2, we sought to increase the selectivity for α(v)β3-mediated cell adhesion by examining the effects of structural changes in both the guanidine mimetic and the substituent α to the carboxylate. To prepare some of the desired aminoimidazoles, a novel reductive amination utilizing a trityl-protected aminoimidazole was developed. It was found that guanidine mimetics with a wide range of pK(a)'s were potent antagonists of α(v)β3. In general, it appeared that an acylated 2-aminoimidazole guanidine mimetic imparted excellent selectivity for α(v)β3-mediated adhesion versus α(IIb)β3-mediated platelet aggregation, with selectivity of approximately 3 orders of magnitude observed for compounds 3g and 3h. It was also found in this series that the α- substituent was required for potent activity and that 2,6-disubstituted arylsulfonamides were optimal. In addition, the selective α(v)β3 antagonist 3h was found to be a potent inhibitor of α(v)β3-mediated cell migration.

Integrin receptor antagonists

This invention relates to novel heterocycles including 3-?1-?3-(imidazolin-2-ylamino)propyl!indazol-5-ylcarbonylamino!-2-(benzyloxycarbonylamino)propionic acid, which are useful as antagonists of the αv β3 integrin and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.